Cinacalcet Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
N/0022 
Minor change in labelling or package leaflet not 
17/04/2023 
connected with the SPC (Art. 61.3 Notification) 
N/0021 
Minor change in labelling or package leaflet not 
12/09/2022 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
II/0016 
B.I.a.1.b - Change in the manufacturer of AS or of a 
22/04/2022 
n/a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
N/0020 
Minor change in labelling or package leaflet not 
06/04/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0019 
B.II.e.1.b.1 - Change in immediate packaging of the 
17/12/2021 
n/a 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
T/0017 
Transfer of Marketing Authorisation 
12/08/2021 
29/09/2021 
SmPC, 
Labelling and 
PL 
IB/0015 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
20/07/2021 
29/09/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
27/05/2021 
17/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0013 
B.II.e.5.a.1 - Change in pack size of the finished 
17/11/2020 
17/06/2021 
SmPC and 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R/0011 
Renewal of the marketing authorisation. 
23/07/2020 
24/09/2020 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Cinacalcet Mylan in the approved indication remains 
favourable and recommended an unlimited validity for the 
Marketing Authorisation. 
II/0009 
B.I.a.1.b - Change in the manufacturer of AS or of a 
03/09/2020 
n/a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/04/2020 
02/06/2020 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0010 
A.7 - Administrative change - Deletion of 
26/02/2020 
02/06/2020 
Annex II and 
manufacturing sites 
PL 
IAIN/0008 
B.II.b.2.c.1 - Change to importer, batch release 
27/01/2020 
02/06/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0007/G 
This was an application for a group of variations. 
18/11/2019 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
Page 4/6 
 
 
 
 
 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0006/G 
This was an application for a group of variations. 
29/10/2019 
02/06/2020 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IB/0005 
C.I.11.z - Introduction of, or change(s) to, the 
17/05/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
N/0004 
Minor change in labelling or package leaflet not 
22/03/2019 
23/08/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/09/2018 
23/08/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Labelling and 
PL 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
IA/0002/G 
This was an application for a group of variations. 
24/05/2017 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IAIN/0001 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
11/01/2017 
11/01/2018 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
